STOCK TITAN

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
IPO offering
Rhea-AI Summary
Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share, expected to generate gross proceeds of $319.0 million. The company's common stock is set to begin trading on the Nasdaq Global Select Market on February 8, 2024, under the ticker symbol 'KYTX.'
Positive
  • None.
Negative
  • None.

The recent announcement by Kyverna Therapeutics regarding the pricing of its initial public offering (IPO) is a significant event for the company and its stakeholders. The decision to price 14,500,000 shares at $22.00 per share, leading to gross proceeds of $319.0 million, is above the typical range for biopharmaceutical companies at this stage. This suggests a strong investor interest and confidence in Kyverna's potential to develop effective cell therapies for autoimmune diseases. The capital raised will likely accelerate their research and development programs, potentially shortening the time to market for their therapies. However, investors should be aware of the inherent risks in the biopharmaceutical sector, including lengthy development timelines and regulatory hurdles.

From a medical research perspective, the successful pricing of Kyverna's IPO is a testament to the growing interest in cell therapy treatments for autoimmune diseases, which represent a significant unmet medical need. The funding will provide Kyverna with the resources to advance its clinical trials and expand its pipeline. Given the complexity and high costs associated with cell therapy research, the influx of capital is crucial. The long-term success of Kyverna's therapies will depend on their efficacy and safety profiles, which are currently under investigation. If successful, these therapies could offer new hope for patients and potentially disrupt the autoimmune disease treatment market.

Entering the Nasdaq Global Select Market is a strategic move for Kyverna Therapeutics, signaling its readiness to operate within the public domain and its commitment to transparency and governance standards. The upsized IPO and the premium pricing indicate market optimism about the company's growth prospects. The biopharmaceutical industry is highly competitive, yet the focus on autoimmune diseases, a niche but rapidly expanding segment, could position Kyverna advantageously. Prospective investors should monitor Kyverna's pipeline progress and industry trends to understand the potential market impact of its cell therapies and the broader implications for the sector.

EMERYVILLE, Calif., Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share. All of the shares are being offered by Kyverna. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kyverna, are expected to be $319.0 million. Kyverna's common stock is expected to begin trading on the Nasdaq Global Select Market on February 8, 2024 under the ticker symbol "KYTX." The offering is expected to close on or about February 12, 2024, subject to the satisfaction of customary closing conditions. In addition, Kyverna has granted the underwriters a 30-day option to purchase up to an additional 2,175,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

J.P. Morgan, Morgan Stanley, Leerink Partners, and Wells Fargo Securities are acting as joint book-running managers for the offering.

A registration statement relating to the offering has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 7, 2024. A copy of the registration statement can be accessed through the SEC's website at www.sec.gov. The offering is being made only by means of a prospectus forming part of the registration statement relating to these securities. When available, copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; and Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Kyverna Therapeutics
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the anticipated size of the initial public offering and the expected trading commencement and closing dates. The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, the satisfaction of customary closing conditions related to the initial public offering, the completion of the initial public offering on the anticipated terms, or at all, and other factors discussed in the "Risk Factors" section of the preliminary prospectus that forms a part of the effective registration statement filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Kyverna Media Contact:
Consort Partners for Kyverna
kyvernatx@consortpartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-pricing-of-upsized-initial-public-offering-302056924.html

SOURCE Kyverna Therapeutics

Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

14,500,000 shares of its common stock are being offered by Kyverna Therapeutics, Inc.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kyverna, are expected to be $319.0 million.

Kyverna Therapeutics, Inc.'s common stock is expected to begin trading on the Nasdaq Global Select Market on February 8, 2024.

The ticker symbol for Kyverna Therapeutics, Inc. is 'KYTX'.

:KYTX

KYTX Rankings

KYTX Latest News

KYTX Stock Data